Yesterday NIH Director Francis Collins approved three more human embryonic stem cell lines for taxpayer funding, bringing the total to 135.
It’s been about a month since the last approvals, and just over three months since the rush to approve a large number of lines. Two of the three new lines from Cedars-Sinai Medical Center appear to have chromosomal abnormalities, as well as to be from destruction of full siblings.
The Obama administration last approved more federal funding for embryonic stem cell research on August 19, when Collins approved four more human embryonic stem cell (hESC) lines for the embryonic stem cell registry.
Those four newest approvals are sold by the company BioTime, Inc., which had two other hESC lines approved June 2, 2011. Details of the embryo destruction and hESC derivation (including from siblings) were published by ESI and Sydney IVF workers in 2007, around the time that ESI abandoned its schemes for therapies based on hESC.